Middle East And Africa Non-Small Cell Lung Cancer Diagnostics Market, By Cancer Type (Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), Large Cell Carcinoma And Others), Product (Reagents And Kits, Instruments, And Services And Softwares) Test(Imaging Test, Molecular Test, Biopsy, Sputum Cytology, Thoracentesis, Immunohistochemistry, And Others), End-User (Hospital, Clinical Laboratories, Academics And Others) Country (South Africa Egypt, Saudi Arabia, UAE, Israel, And Rest Of Middle East And Africa,) Industry Trends And Forecast To 2028.
Market Analysis and Insights: Middle East And Africa Non-Small Cell Lung Cancer Diagnostics Market
Middle East and Africa non-small cell lung cancer diagnostics market is expected to reach USD 122.49 million by 2028 from USD 50.72 million in 2020, growing at a steady CAGR of 11.7% in the forecast period of 2021 to 2028.
Non-small cell lung cancer is a disease in which malignant cells or cancer cells are formed in the tissues of the lungs. These are of different types, and each type has different cancer cells that grow and spread in different ways. The non-small cell lung cancer (NSCLC) types are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. In squamous cell carcinoma, the cancer forms in the thin, flat cells lining inside the lungs and is called epidermoid carcinoma. Large cell carcinoma cancer begins in several types of large cells. The adenocarcinoma type of cancer begins in the cells that line the alveoli and make substances such as mucus. One of the significant risks for non-small cell lung cancer (NSCLC) is that smoking and symptoms include a cough that doesn’t go away and shortness of breath. Various tests are used, such as imaging tests, molecular tests, biopsies, and others, to diagnose and examine the cancer stage. Diagnosis is essential to identify the disease in time so that proper treatment could be given to patients. The factors driving the growth of the non-small cell lung cancer diagnostics market are the usage of artificial intelligence and machine learning to improve diagnostics. At the same time, the high cost of instrumentation may restrain the market growth of the non-small cell lung cancer diagnostics market growth.
Moreover, novel technological advancements in the diagnosis and treatment may act as an opportunity towards growth in the non-small cell lung cancer diagnostics market. On the other hand, disruption in the supply chain due to covid-19 impact is a challenge to the market
The non-small cell lung cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the non-small cell lung cancer diagnostics market scenario, contact Data Bridge Market Research for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
Middle East And Africa Non-Small Cell Lung Cancer Diagnostics Market Scope And Market Size
The Middle East and Africa non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of cancer type, the non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), large cell carcinoma, and others. In 2021, the lung adenocarcinoma (LUAD) segment is expected to dominate the non-small cell lung cancer diagnostics market due to the prevalence of LUSC cancer in the region.
- On the basis of products, the non-small cell lung cancer diagnostics market is segmented into reagents and kits, instruments and services, and software. In 2021, the instrument segment is expected to dominate the non-small cell lung cancer diagnostics market due to the wide adaptability of instruments such as X-rays for cancer diagnosis purposes.
- On the basis of tests, the non-small cell lung cancer diagnostics market is a segmented imaging test, molecular test, biopsy, sputum cytology, thoracentesis, immunohistochemistry, and others. In 2021, the molecular test segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing usage of molecular-based diagnostic procedures
- On the basis of end-users, the non-small cell lung cancer diagnostics market is segmented into hospitals, clinical laboratories, academics, and others. In 2021, the clinical laboratories segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing R&D in clinical research
Middle East And Africa Non-Small Cell Lung Cancer Diagnostics Market: Country Level Analysis
Middle East And Africa non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user.
Countries covered in the Middle East and Africa non-small cell lung cancer diagnostics market report are South Africa, Egypt, Saudi Arabia, UAE, Israel, and the rest of the Middle East and Africa.
Saudi Arabia is expected to dominate the Middle East and Africa non-small cell lung cancer diagnostics market with the highest CAGR and highest market share due to growing cases of cancer in Saudi Arabia. Israel is expected to dominate the market due to the increased adaptability of machine learning and technological advancement. South Africa is dominating the market due to growing lung cancer cases in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Rising Demand Of Diagnostic In Medical Setting
Middle East and Africa non-small cell lung cancer diagnostics market also provide you with detailed market analysis for every country growth in the industry with sales, components sales, the impact of technological development in non-small cell lung cancer diagnostics, and changes in regulatory scenarios with their support for the non-small cell lung cancer diagnostics market. The data is available for the historical period 2010 to 2019.
Competitive Landscape And Middle East And Africa Non-Small Cell Lung Cancer Diagnostics Market Share Analysis
Middle East and Africa non-small cell lung cancer diagnostics market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, India presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to the non-small cell lung cancer diagnostics market.
Some of the major players operating in the non-small cell lung cancer diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Incorporated, NeoGenomics Laboratories, Inc., Janssen Pharmaceutical NVbioMérieux SA, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Dr. Lal PathLabs, Oncimmune, among others.
The Middle East and Africa non-small cell lung cancer diagnostics markets are fragmented, and the major players have used various strategies such as collaborations, recognitions, agreements, and others, to increase their footprints in the non-small cell lung cancer diagnostics market.
For instance,
- In June 2020, F. Hoffmann-La Roche Ltd launched an automated digital pathology algorithm, uPath PD-L1 (SP263) image analysis, to diagnose non-small cell lung cancer (NSCLC) and improve the speed and accuracy of diagnosis treatment
SKU-